

## Mozambique

### Support for Vaccine: DTP-HepB-Hib

This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Mozambique																										
2. Vaccine grant number:	08-MOZ-08b-Y, 1013-MOZ-04C-X, 1415-MOZ-04c-X, 1617-MOZ-04c-X, 1819-MOZ-04c-X, 20-MOZ-04c-X, MOZ-Lumpsum-1																										
3. Date of Decision Letter:	30 September 2019																										
4. Date of the Partnership Framework Agreement:	06 December 2013																										
5. Programme title:	New Vaccine Support (NVS), DTP-HepB-Hib, Routine																										
6. Vaccine type:	DTP-HepB-Hib																										
7. Requested product presentation and formulation of vaccine:	Penta, 10 dose(s) per vial, LIQUID																										
8. Programme Duration: <sup>1</sup>	2001-2020																										
9. Programme Budget (indicative): <sup>2</sup>	(subject to the terms of the Partnership Framework Agreement, if applicable)																										
	2001-2019	2020	2021	2022	2023	2024	Total <sup>2</sup>																				
Programme Budget (US\$)	64,391,187	228,500	-	-	-	-	64,619,687																				
10. Vaccine introduction grant	<table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th colspan="3">Approval</th> </tr> <tr> <th>Year</th> <th>Grant Number</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>2002</td> <td>MOZ-Lumpsum-1</td> <td>100,000</td> </tr> <tr> <td>2008</td> <td>08-MOZ-08b-Y</td> <td>288,500</td> </tr> </tbody> </table> <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th colspan="2">Disbursement</th> </tr> <tr> <th>Disbursement date</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>30 September, 2002</td> <td>100,000</td> </tr> <tr> <td>28 October, 2008</td> <td>288,500</td> </tr> </tbody> </table>							Approval			Year	Grant Number	Amount (US\$)	2002	MOZ-Lumpsum-1	100,000	2008	08-MOZ-08b-Y	288,500	Disbursement		Disbursement date	Amount (US\$)	30 September, 2002	100,000	28 October, 2008	288,500
Approval																											
Year	Grant Number	Amount (US\$)																									
2002	MOZ-Lumpsum-1	100,000																									
2008	08-MOZ-08b-Y	288,500																									
Disbursement																											
Disbursement date	Amount (US\$)																										
30 September, 2002	100,000																										
28 October, 2008	288,500																										
11. Product switch grant	Not applicable																										

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

**12. Indicative Annual Amounts:**<sup>3</sup> (subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2001-2019	2020
Number of vaccine doses		315,900
Annual Amounts (US\$)	64,391,187	228,500

**13. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**14. Self-procurement:** Not applicable

**15. Co-financing obligations:**

According to the co-financing policy, the Country falls within the group: Initial self-financing

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020
Number of vaccine doses	121,500
Number of AD syringes	-
Number of re-constitution syringes	-
Number of safety boxes	-
Value of vaccine doses (US\$)	84,819
Total co-financing payments (US\$) (including freight)	87,500

**16. Operational support for campaigns:**

Not applicable

**17. Additional Reporting Requirements:**

	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	<p>31 March 2020</p> <p>15 May 2020</p>
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Gavi Secretariat</p>

**18. Financial clarifications:**

Not applicable

**19. Other conditions:**

Not applicable

Signed by,  
**On behalf of Gavi**



Thabani Maphosa,  
Managing Director, Country Programmes  
30 September 2019